Increasing HPV vaccination through policy for public health benefit
Heather M Brandt, Jennifer Young Pierce, Ashley Crary, Heather M Brandt, Jennifer Young Pierce, Ashley Crary
Abstract
Vaccines against specific types of human papillomavirus (HPV) linked to cancer and other diseases have been met with mixed acceptance globally and in the United States. Policy-level interventions have been shown to be effective in increasing public health benefit. Government policies and mandates may result in improved HPV vaccination coverage and reduced disease burden, and alternative policies that improve unhindered access to HPV vaccination may allow success as well. The purpose of this commentary is to summarize policy efforts to maximize the public health benefit of HPV vaccination. We examine selected examples of HPV vaccination policy in global contexts and in the United States.
Keywords: HPV; HPV vaccination; cancer prevention; public health intervention; public health policy; vaccination.
References
- World Health Organization Human papillomavirus vaccines: WHO position paper. Weekly epidemiological record, 24 October 2014, 89th Year; 89:465-92.
- Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007; 56:1-24; PMID:17380109
- Whitney CG, Zhou F, Singleton J, Schuchat A. Benefits from immunization during the vaccines for children program era - United States, 1994-2013. MMWR Morb Mortal Wkly Rep 2014; 63:352-5; PMID:24759657
- Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44; PMID:21067976;
- Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346:f2032; PMID:23599298;
- Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ 2012; 90:623-8; PMID:22893746;
- Barbaro B, Brotherton JM. Measuring HPV vaccination coverage in Australia: comparing two alternative population-based denominators. Aust N Z J Public Health 2015; 39:326-30; PMID:26094817;
- Flaherty DK. The vaccine-autism connection: a public health crisis caused by unethical medical practices and fraudulent science. Ann Pharmacother 2011; 45:1302-4; PMID:21917556;
Source: PubMed